Nathalie Scholler Laboratory

Home > Publications




Prantner, A., Nguyen, C.V., Scholler N. "Facile immunotargeting of nanoparticles against tumor antigens using site-specific biotinylated antibody fragments". Journal of Biomedical Nanotechnology. (in press)

Nunez-Cruz, S. and Scholler N. "Immunocompetent mouse model of ovarian cancer for in vivo imaging" chapter of “Ovarian Cancer”, Humana Press editors (in press)

Dangaj D, Lanitis E, Zhao A, Joshi S, Cheng Y, Sandaltzopoulos R, Ra HJ, Danet-Desnoyers G, Powell DJ Jr, Scholler N. "Novel recombinant human B7-H4 antibodies overcome tumoral immune escape to potentiate T cell anti-tumor responses". Cancer Res. 2013 May 30 [PDF]


Selene Nunez-Cruz, Phyllis A. Gimotty, Matthew W. Guerra, Denise C. Connolly, You-Qiang Wu, Robert A. DeAngelis, John D. Lambris, George Coukos and Nathalie Scholler. “Genetic and pharmacologic inhibition of complement impairs endothelial cell function and ablates ovarian cancer neovascularization”. Neoplasia, Volume 14, number 11, Nov 2012. [PDF]

Andrew Prantner, Jun Chen, Christopher Murray, and Nathalie Scholler. "Coating Evaluation and Purification of Monodisperse, Water-Soluble, Magnetic Nanoparticles Using Sucrose Density Gradient Ultracentrifugation". Chemistry of Materials, 2012, 24, 4008-4010. [PDF]

Yonghai Li, Donald L Siegel, Nathalie Scholler and David E Kaplan. Glypican-3-specific scFv isolation and validation for use in hepatocellular carcinoma. BMC Biotechnology 2012, 12:23. [PDF]

Katarzyna Urbanska, Evripidis Lanitis, Mathilde Poussin, Rachel Lynn, Brian P Gavin, Sander Kelderman, Jason Yu, Nathalie Scholler and Daniel J Powell Jr. A novel immune receptor expressed by T cells for universal targeting of diverse and multiple tumor associated antigens. Cancer Research 2012. [PDF]

Nathalie Scholler. "Selection of antibody fragments by yeast display". Methods in Molecular Biology 1, Antibody Engineering, Volume 907, Part 3, Pages 259-280, Humana Press editors. [PDF]

Gina M. Mantia-Smaldone and Nathalie Scholler. "Preventive Strategies in Epithelial Ovarian Cancer". Ovarian Cancer, volume 1, Chapter 2, Pages 15-42, InTech Open Access publisher. ISBN: 978-953-307-810-6 [PDF]

Janos L. Tanyi and Nathalie Scholler. Oncology biomarkers for detection and therapeutic monitoring of Gynecologic malignancies. Frontiers in Biosciences 2012 Jan 1;4:1097-110. [PDF]


Dangaj D, Abbott K, Mookerjee A, Zhao A, Kirby PS, Sandaltzopoulos R, Powell DJ, Lamaziere A, Siegel DL, Wolf C, and Scholler, N. Mannose receptor engagement by mesothelin GPI anchor polarizes tumor-associated and is blocked by a recombinant antibody directed against mannose receptor domain 4. PLos ONE  [Online Dec 6] [PDF]

Lanitis E, Poussin M, Hagemann I, Sandaltzopoulos R, Scholler N, and Powell DJ. Redirected anti-tumor activity of primary human lymphocytes transduced with a fully-human anti-mesothein chimeric receptor. Molecular Therapy [Online Nov 29]  [PDF]

Kalogera E, Scholler N, Powless C, Weaver A, Drapkin R, Li J, Jiang SW, Podratz K, Urban N, Dowdy SC. Correlation of serum HE4 with tumor size and myometrial invasion in endometrial cancer. Gynecologic Oncology [online October 28] [PDF]

Urban N, Thorpe JD, McIntosh M, Bergan L, Forrest R, Kampani A, Scholler N, O'Briant K, Descher C, Berg C. Potential role of HE4 in multimodal screening for epitelial ovarian cancer. JNCI brief communication 2011; 103:1-5 [Epub ahead of print]. [PDF]

Sasaroli D, Gimotty PA, Pathak HB, Hammond R, Kougioumtzidou E, Katsaros D, Buckanovich R, Devarajan K, Sandaltzopoulos R, Godwin AK, Scholler N, Coukos G. Novel surface targets and serum biomarkers from the ovarian cancer vasculature. Cancer Biol Ther. 2011 Aug 1;12(3). [Epub ahead of print] PubMed PMID: 21617380 [PDF]

Cramer DW, Bast RC Jr, Berg CD, Diamandis EP, Godwin AK, Hartge P, Lokshin AE, Lu KH, McIntosh MW, Mor G, Patriotis C, Pinsky PF, Thornquist MD, Scholler N, Skates SJ, Sluss PM, Srivastava S, Ward DC, Zhang Z, Zhu CS, Urban N. Ovarian cancer biomarker performance in prostate, lung, colorectal, and ovarian cancer screening trial specimens. Cancer Prev Res (Phila). 2011 Mar;4(3):365-74. [PDF]

Zhu CS, Pinsky PF, Cramer DW, Ransohoff DF, Hartge P, Pfeiffer RM, Urban N, Mor G, Bast RC Jr, Moore LE, Lokshin AE, McIntosh MW, Skates SJ, Vitonis A, Zhang Z, Ward DC, Symanowski JT, Lomakin A, Fung ET, Sluss PM, Scholler N, Lu KH, Marrangoni AM, Patriotis C, Srivastava S, Buys SS, Berg CD; PLCO Project Team. A framework for evaluating biomarkers for early detection: validation of biomarker panels for ovarian cancer. Cancer Prev Res (Phila). 2011 Mar;4(3):375-83. [PDF]



Nunez-Cruz S., Connolly D.C. and Scholler N., “An orthotopic model of serous ovarian cancer in immunocompetent mice for in vivo tumor imaging and monitoring of tumor immune responses.” JoVE , 2010 Nov 28 . [Epub ahead of print][PDF]

Zhao A., Nunez-Cruz S., Li C., Coukos G., Siegel D.L. and Scholler N. “Rapid isolation of high affinity human antibodies against the tumor vascular marker Endosialin/TEM1, using a paired yeast display/secretory scFv library platform.”. JIM, 2010 Sep 15. [Epub ahead of print] [PDF]

Scholler N. Novel targeting strategies using recombinant antibodies for early diagnosis and therapy of ovarian cancer. – Future Medicine Therapy. 2010, 7(3), 209-212 [PDF]

Tanyi J.L and Scholler N. “From the endometrium physiology to a comprehensive strategy for the discovery of ovarian cancer biomarkers.” Oncology reviews. 2010 March, Vol. 4, Number 1, pages 43-50. [PDF]

Anderson G.L., McIntosh M., Wu L., Thorpe J.D., Bergan L., Goodman G., Barnett M., Thornquist M.D., Scholler N., Kim N., O’Briant K., Drescher C., Urban N.. “Assessing Lead Time of Selected Ovarian Cancer Biomarkers: A Nested Case-Control Study” –JNCI.  2010 Vol. 102, Issue 1, January 6. [PDF]


C. Shah, K. Lowe, P. Paley, E. Wallace, G. Anderson, M. McIntosh, R. Andersen, N. Scholler, L. Bergan, J. Thorpe, N. Urban, C. Drescher. “Influence of ovarian cancer Risk status on the Diagnostic Performance of the serum Biomarkers Mesothelin. HE4 and CA125”.-Cancer Epidemiology Biomarkers & Prevention (CEBC) Prev. 2009 May;18(5):1365-72 [PDF]

Andersen MR, Goff BA, Lowe KA, Scholler N, Bergan L, Drescher CW, Paley P and Urban N. “Use of a Symptom Index, CA125, and HE4 to predict ovarian cancer.” -Gynecol Oncol. 2010 Mar;116(3):378-83. Epub 2009 Nov 28. [PDF]

Chen, A., Kozak, D., Battersby, B.J., Forrest, R.M., Scholler, N., Urban, N., and Trau, M. “Antifouling Surface Layers for Improved Signal-to-Noise of Particle-Based Immunoassays” Langmuir. 2009, 25 (23), pp 13510–13515 [PDF]

Sasaroli D., Coukos G. and Scholler N. “Beyond CA125: the coming of age of ovarian cancer biomarkers. Are we there yet?” - Biomarkers in Medicine.  Prev. 2009 May;18(5):1365-72 [PDF]

Gonzalez, J.M., Ofori E., Burd I., Chai J., Scholler N., Elovitz M.A.: “Maternal mortality from systemic illness: unraveling the contribution of the immune response”. Am J Obstet Gynecol 2009, 200, 430 e1-8. [PDF]


Scholler N., Gross JA., Garvik B., Wells L., Liu Y., Loch CM., Ramirez AB., McIntosh MW., Lampe PD., Urban N. Use of cancer-specific yeast-secreted in vivo biotinylated recombinant antibodies for serum biomarker discovery. Journal of Translational Medicine. 2008, 6:41 [PDF]

Scholler, N., Mesothelin, Encyclopedia of Cancer, 2nd edition, 1836-1940 (2008) [PDF]

Lowe K., Shah C., Wallace E., Anderson G., Paley P., McIntosh M., Andersen R., Scholler N., Bergan L., Thorpe J., Urban N., Drescher C. Effects of Personal Characteristics on Serum CA125, Mesothelin, and HE4 Levels in Healthy Post-menopausal Women at High-Risk for Ovarian Cancer. Cancer Epidemiology, Biomarkers & Prevention. 2008 Sep;17(9):2480-7.[PDF]

Palmer C., Duan X., Hawley S., Scholler N., Thorpe J., Sahota R., Wong M., Wray A., Drescher C., McIntosh M., Brown P., Nelson B., Urban N.  Systematic Evaluation of Candidate Blood Markers for Detecting Ovarian Cancer. PLoS ONE - 2008 Jul 9;3(7):e2633. [PDF]

Faca, V., Song, K., Wang, H., Zhang, Q., Krasnoselsky, A., Ireton, R., Newcomb, L., Plentz, R., Glukhova, V., Phanstiel, D., Gurumurthy, S., Redston, M. S., Brenner, D., Anderson, M., Misek, D., Scholler, N., Urban, N., Barnett, M., Edelstein, C., Goodman, G., Thornquist, M., McIntosh, M., DePinho, R. A., Bardeesy, N. and Hanash S. Markers for human pancreatic cancer based on plasma proteome analysis of a mouse model. PLoS Med. 2008 Jun 10;5(6):e123. [PDF]

Andersen MR, Goff BA, Lowe KA, Scholler N, Bergan L, Dresher CW, Paley P, Urban N. Combining a symptoms index with CA 125 to improve detection of ovarian cancer. Cancer. 2008 Jun 25. Jun 25;113(3):484-489.DOI: 10.1002/cncr.23577 [PDF]

Scholler, N., Lowe, K. A., Bergan, L. A., Kampani, A. V., Ng, V., Forrest, R. M., Thorpe, J. D.,  Gross, J. A., Garvik, B. M., Drapkin, R., Anderson, G. L. and Urban, N. Use of yeast-secreted in vivo biotinylated recombinant antibodies (biobodies) in bead–based ELISA. Clinical Cancer Research. 2008 May 1:14(9):2647-55 [PDF]

Scholler publications, before the Scholler lab

Scholler, N. and Urban N. CA125 in Ovarian Cancer. Biomarkers in Medicine 1(4), December 2007, Pages 513-523. [PDF]

Loch, C. M., Ramirez, A. B., Liu, Y., Sather, C. L., Delrow, J.J., Garvik, B., Scholler, N., Urban, N., McIntosh, M. W. and Lampe, P. D.  Use of High Density Antibody Arrays to Validate and Discover Cancer Serum Biomarkers. Molecular Oncology. Volume 1, Issue 3, December 2007, Pages 313-320 [PDF]

Bergan, L., Gross, J. A., Nevin, B., Urban, N., and Scholler, N. 2007. Development and in vitro validation of anti-mesothelin biobodies that prevent CA125/Mesothelin-dependent cell attachment. Cancer Letters. Oct 8; 255(2):263-74. Epub 2007 Jun 7. [PDF]

Scholler, N., Garvik, B., Hayden-Ledbetter, M., Kline, T. and Urban, N. 2007. Development of a CA125-Mesothelin cell adhesion assay as a screening tool for biologics discovery. Cancer Letters. Mar 8; 247(1):130-136. Epub 2006 May 4. [PDF]

Scholler, N., Garvik, B., Quarles, T., Jiang, S. and Urban, N. 2006. Method for generation of in vivo biotinylated recombinant antibodies by yeast mating. Journal of Immunological Methods. Dec 20; 317(1-2):132-143. Epub 2006 Oct 30. [PDF]

Scholler, N., Crawford, M., Sato, A., Drescher, C. W., O’Briant, K. C., Kiviat, N., Anderson, G. L. and Urban, N. Bead-based ELISA assays for validation of ovarian cancer early detection markers. Clinical Cancer Research. 2006. 12: 2117-2124. [PDF]

McIntosh, M. W., Drescher, C., Karlan, B., Scholler, N., Urban, N., Hellström, I. and Hellström, K. E. 2004. Combining CA 125 and SMR serum markers for diagnosis and early detection of ovarian carcinoma. Gynecologic Oncology. 95(1):9-15. [PDF]

Disis, M. L.+, Scholler, N.+, Dahlin, A., Pullman, J., Knutson, K. L., Hellström, K. E. and Hellström, I. 2003. Plasmid-based vaccines encoding rat neu and immune stimulatory molecules can elicit rat neu-specific immunity. Molecular Cancer Therapy. Oct; 2(10):995-1002.(+these authors equally contributed to the work). [PDF]

Scholler, N., Hayden-Ledbetter, M., Dahlin, A., Hellström, I., Hellström, K. E. and Ledbetter, J. A. 2002. CD83 Regulates the Development of Cellular Immunity. Journal of Immunology. 168: 2599-2602. [PDF]

Scholler, N., Hayden-Ledbetter, M., Hellström, I., Hellström, K. E. and Ledbetter, J. A. 2001. CD83 is a Sialic Acid-Binding Immunoglobin-Like Lectin (Siglec) Adhesion Receptor that Binds Monocytes and a Subset of Activated CD8+ T Cells. Journal of Immunology. 166: 3865-3872. [PDF]

Hellström, I., Ledbetter, J. A., Scholler, N., Yang, Y., Ye, Z. M., Goodman, G. E., Pullman, J., Hayden-Ledbetter, M. and Hellström, K. E. 2001. CD3-mediated activation of tumor-reactive lymphocytes from patients with advanced cancer. Proceedings of the National Academy of Sciences of the United States of America. Jun 5; 98(12): 6783-6788. [PDF]

Scholler, N., Fu, N., Yang, Y., Ye, Z. M., Goodman, G. E., Hellström, K. E. and Hellström, I.  1999. Soluble member(s) of the mesothelin/megakaryocyte potentiating factor family are detectable in sera from patients with ovarian carcinoma. Proceedings of the National Academy of Sciences of the United States of America. 96(20):11531-11536. [PDF]

publications AS N. Buonavista (Maiden Name)

Couissiner-Paris, P., Bourgeois, A., Dessein, H., Bacellar, O., Rodriguez, V. Jr., Kohlstadt, S., Buonavista, N., Pene, J. and Dessein, A. J. 1995. Identification of a major T cell immunogen in the anti-schistosome response of adult residents in an area endemic of Schistosoma mansoni. European Journal of Immunology. 24 (4): 903-910. [PDF]

Cornillon, S., Foa, C., Davoust, J., Buonavista, N., Gross, J. D. and Golstein, P. 1994. Programmed cell death in Dictyostelium. Journal of Cell Science. Oct; 107(10): 2691-2704. [PDF]

Buonavista, N., Balzano, C., Pontarotti, P., Le Paslier, D. and Golstein, P. 1992. Molecular linkage of human CTLA-4 and CD28 Ig-superfamily genes in yeast artificial chromosomes. Genomics. Jul; 13(3):856-861. [PDF]

Balzano, C., Buonavista, N., Rouvier, E. and Golstein, P. 1992. CTLA-4 CD28, similar protein, neighboring genes. International Journal of Cancer. Suppl 7, 28-32